Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06170268 · ClinicalTrials.gov registry record
Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)
A clinical trial of Alzheimer Disease, sponsored by Alzheimer's Disease and Related Disorders Association.
- Recruiting
- Registry status
- 20,000
- Enrollment target
- 1
- Study location
NCT06170268 is a study of Alzheimer Disease that is actively recruiting participants, run by Alzheimer's Disease and Related Disorders Association. The registered enrollment target is 20,000 participants, above the 2,685-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (645% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06170268, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Alzheimer's Disease and Related Disorders Association.
- RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect longitudinal clinical and safety data for enrolled patients being evaluated for or treated with novel FDA-approved Alzheimer's disease (AD) therapies. ALZ-NET is a longitudinal registry with an expandable platform, designed to grow with scientific and medical advancements. As new treatments are approved and implemented in care, ALZ-NET will track the long-term health outcomes associated with their use in a real-world setting. ALZ-NET is a resource for evidence gathering, information sharing and education across clinical and research communities, encouraging innovative research and supporting opportunities to improve clinical care delivery. All participating physicians and site staff will complete comprehensive training to ensure adherence of data requirements and registry timelines.
Conditions Studied
Interventions
- OTHER Routine Care Documentation
Study Locations (1)
Illinois
- Full List of Active Sites - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2032-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06170268
The ClinicalTrials.gov registry entry for NCT06170268 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,685-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (645% higher). The listed sponsor is Alzheimer's Disease and Related Disorders Association, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Routine Care Documentation is the first listed.
NCT06170268 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06170268 about?
NCT06170268 is a clinical study titled "Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)". The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect longitudinal clinical and safety data for enrolled patients being evaluated for or treated with novel FDA-approved Alzheimer's disease (AD) therapies. ALZ-NET is a longitudinal registry with an expandable platform, designed...
What is the current status of trial NCT06170268?
This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2022-10-20. Estimated completion is 2032-12.
What conditions does trial NCT06170268 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06170268?
The interventions under investigation include: Routine Care Documentation (OTHER).
Who is sponsoring clinical trial NCT06170268?
This trial is sponsored by Alzheimer's Disease and Related Disorders Association, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06170268 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.